TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1514295

Group type: EXPERIMENTAL
Intervention: Fibrin sealant for bronchial stump occlusions
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Fibrin sealant for gastrointestinal operations
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Fibrin sealant for emergency abdominal operations
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Fibrin sealant for elective surgery
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Fibrin sealant for pancreatic duct occlusion after Whipple's operation
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Fibrin sealing for prevention of postoperative lymph fistulae
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Instillation of fibrin for existing lymph fistulae
Number of subjects: 190
Study: 6337698

Group type: EXPERIMENTAL
Intervention: Preoperative chemoendocrine regimen followed by postoperative radiotherapy
Number of subjects: 184

Group type: COMPARATOR
Intervention: Preoperative chemoendocrine regimen without postoperative radiotherapy
Number of subjects: 184
Study: 30514651

Group type: EXPERIMENTAL
Intervention: Parental incarceration
Number of subjects: 3972

Group type: EXPERIMENTAL
Intervention: Maternal incarceration
Number of subjects: 3972

Group type: EXPERIMENTAL
Intervention: Paternal incarceration
Number of subjects: 3972

Group type: EXPERIMENTAL
Intervention: Parental incarceration before age 10
Number of subjects: 3972
Study: 29458927

Group type: EXPERIMENTAL
Intervention: Olfactory mental imagery (test group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 80
Study: 26819104

Group type: EXPERIMENTAL
Intervention: Early enteral tube feeding in addition to standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care with intravenous rehydration
Number of subjects: 0
Study: 24516621

Group type: EXPERIMENTAL
Intervention: Diet (D) treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Exercise (E) treatment
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study: 21471562

Group type: EXPERIMENTAL
Intervention: ChemoEd intervention (DVD, question-prompt list, self-care information, education consultation ≥24 h before first treatment, telephone follow-up 48 h after first treatment, face-to-face review immediately before second treatment)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: ChemoEd intervention
Number of subjects: 192
Study: 20217071

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 79
Study: 17693650

Group type: COMPARATOR
Intervention: VAD-doxil
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: TVAD-doxil
Number of subjects: 232
Study: 16183965

Group type: EXPERIMENTAL
Intervention: Protein and carbohydrate (PC) supplementation after resistance exercise
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo (NON)
Number of subjects: 6
Study: 12137177

Group type: EXPERIMENTAL
Intervention: Implicit learning group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit learning group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 9820296

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (8 million IU every other day subcutaneously)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b
Number of subjects: 718
Study: 7626346

Group type: EXPERIMENTAL
Intervention: Streptokinase 1.5 million units over 30 min (n = 57)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (n = 55)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ST depression ≥ 3 mm
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: ST depression ≥ 2 mm
Number of subjects: 112
Study: 2466846

Group type: EXPERIMENTAL
Intervention: Antithrombin III and low-dose heparin
Number of subjects: 83

Group type: COMPARATOR
Intervention: Dextran 40
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Antithrombin III and low-dose heparin (in cemented prosthesis group)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Dextran 40 (in cemented prosthesis group)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Antithrombin III
Number of subjects: 83
Study: 404763

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Surgical treatment
Number of subjects: 96
Study: 31682462

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: NIV
Number of subjects: 196
Study: 29747140

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Escitalopram group
Number of subjects: 32
Study: 25796036

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Rock music
Number of subjects: 20

Group type: COMPARATOR
Intervention: No music (sham procedure)
Number of subjects: 20
Study: 23907610

Group type: EXPERIMENTAL
Intervention: Patient-specific instruments
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional instruments
Number of subjects: 100
Study: 20203546

Group type: EXPERIMENTAL
Intervention: remifentanil 1 microg/kg
Number of subjects: 66

Group type: COMPARATOR
Intervention: lidocaine 1.5 mg/kg and esmolol 1.0 mg/kg
Number of subjects: 66
Study: 18986416

Group type: EXPERIMENTAL
Intervention: Tissue Doppler echocardiography
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Myocardial performance index (MPI)
Number of subjects: 32
Study: 16075981

Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between Montelukast sodium and Loratadine
Number of subjects: 0
Study: 11960947

Group type: EXPERIMENTAL
Intervention: Vitamin C (1,500 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 9534832

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily) for 1 week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily) for 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg daily) for 8 weeks in depressed patients
Number of subjects: 0
Study: 7892447

Group type: EXPERIMENTAL
Intervention: Cine phase-contrast with respiratory compensation (CPC-R)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cine phase-contrast without respiratory compensation (CPC)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Phase-contrast with two signals acquired (PC-2)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Phase-contrast with eight signals acquired (PC-8)
Number of subjects: 14
Study: 2795761

Group type: EXPERIMENTAL
Intervention: Endothelial cell seeded grafts at a density of 3500 cells/cm2
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham seeded grafts with culture medium
Number of subjects: 23
Study: 202906

Group type: EXPERIMENTAL
Intervention: Polyc chemotherapy, high-dosage vitamin-A treatment, Endoxan, immunotherapy, and proteolytic enzymes in 5 combinations of therapy
Number of subjects: 56
Study: 30998816

Group type: EXPERIMENTAL
Intervention: Self-reported hearing aid use
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: Poorer measured hearing
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: Higher Hearing Handicap Inventory-Screening scores
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: Access to health insurance coverage
Number of subjects: 1898

Group type: EXPERIMENTAL
Intervention: Place of residence
Number of subjects: 1898
Study: 28329240

Group type: EXPERIMENTAL
Intervention: Oxygen-enriched air (FiO2 0.50, hyperoxia)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Ambient air (FiO2 0.21, normoxia)
Number of subjects: 22
Study: 26086082

Group type: EXPERIMENTAL
Intervention: Game On: Know Alcohol (GOKA) intervention, a school-based alcohol social marketing program
Number of subjects: 2114
Study: 23228249

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 125

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 125
Study: 22124642

Group type: EXPERIMENTAL
Intervention: Traditional lower blepharoplasty and routine lateral canthopexy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lower blepharoplasty with fat bags transposition and routine lateral canthopexy
Number of subjects: 50
Study: 19567927

Group type: EXPERIMENTAL
Intervention: Perceived caffeine condition
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Perceived placebo condition
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 15
Study: 16948122

Group type: EXPERIMENTAL
Intervention: Postoperative interferon‐α therapy (Group 1)
Number of subjects: 155

Group type: COMPARATOR
Intervention: No postoperative interferon‐α therapy (Group 2)
Number of subjects: 155
Study: 15019657

Group type: EXPERIMENTAL
Intervention: CNI-free immunosuppressive regimen (mycophenolate mofetil (MMF) and sirolimus (Sir))
Number of subjects: 30

Group type: COMPARATOR
Intervention: CNI-based immunosuppression (control group)
Number of subjects: 30
Study: 11318053

Group type: EXPERIMENTAL
Intervention: Warning Stimulus (WS) followed by Imperative Stimulus (IS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unintentional contributions to nonspecific preparation
Number of subjects: 0
Study: 9135342

Group type: EXPERIMENTAL
Intervention: 20 ml of 0.5% bupivacaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no bupivacaine)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Both groups (bupivacaine and control)
Number of subjects: 40
Study: 7931470

Group type: EXPERIMENTAL
Intervention: High-dose etoposide and cisplatin (EP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard-dose etoposide and cisplatin (EP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Nonrandomized standard-dose therapy
Number of subjects: 90
Study: 2902738

Group type: EXPERIMENTAL
Intervention: CQP 201-403 (0.01 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CQP 201-403 (0.02 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CQP 201-403 (0.03 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 29778586

Group type: EXPERIMENTAL
Intervention: Two visits at 3 and 6 weeks postpartum (intervention)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Routine care with a single 6-week postpartum visit (control)
Number of subjects: 200
Study: 30645844

Group type: EXPERIMENTAL
Intervention: Yiqi Huaju Recipe (YHR) + routine Western drugs
Number of subjects: 96

Group type: COMPARATOR
Intervention: placebo + routine Western drugs
Number of subjects: 96
Study: 26603252

Group type: EXPERIMENTAL
Intervention: Iron pyrophosphate (approximately 1 mg/kg) daily until 9 months of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo daily until 9 months of age
Number of subjects: 0
Study: 23562680

Group type: EXPERIMENTAL
Intervention: Bitter food consumption (variety of items consumed, unweighted score)
Number of subjects: 2327

Group type: EXPERIMENTAL
Intervention: Bitterness-weighted score
Number of subjects: 2327

Group type: EXPERIMENTAL
Intervention: Educational level
Number of subjects: 2327
Study: 20946752

Group type: EXPERIMENTAL
Intervention: Standard individual cognitive behavioral therapy (CBT) for alcohol use disorders
Number of subjects: 158

Group type: COMPARATOR
Intervention: Female-specific CBT for alcohol use disorders
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Alcohol behavioral couple therapy
Number of subjects: 158

Group type: COMPARATOR
Intervention: Blended individual CBT and alcohol behavioral couple therapy
Number of subjects: 158
Study: 18093797

Group type: EXPERIMENTAL
Intervention: Weigl‐R (modified version of the Weigl Color Form Sorting Test)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Weigl‐R
Number of subjects: 85
Study: 15246968

Group type: EXPERIMENTAL
Intervention: 0.1 mg oral solution of GI181771X
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 0.5 mg oral solution of GI181771X
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 1.5 mg oral solution of GI181771X
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: 5.0 mg tablet of GI181771X
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 11167667

Group type: EXPERIMENTAL
Intervention: Inogatran (thrombin inhibitor) administered intravenously; specific dosage and duration not mentioned.
Number of subjects: 1026
Study: 9626201

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg intravenously every 3 to 4 weeks)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Placebo (intravenously every 3 to 4 weeks)
Number of subjects: 382
Study: 7881452

Group type: EXPERIMENTAL
Intervention: Analgesic plus caffeine (C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Analgesic alone (A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 0
Study: 3295599

Group type: EXPERIMENTAL
Intervention: Defibrotide (400 mg b.i.d. by IV route)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Calcium heparin (5000 I.U. t.i.d. s.c.)
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Defibrotide
Number of subjects: 184

Group type: COMPARATOR
Intervention: Calcium heparin
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Defibrotide and Calcium heparin
Number of subjects: 184
Study: 31647010

Group type: EXPERIMENTAL
Intervention: IMPETUS-D intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual training opportunities (control)
Number of subjects: 24
Study: 30070110

Group type: EXPERIMENTAL
Intervention: Catalytic Janus colloids with controlled rotary motion and gravity influence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catalytic Janus colloids interacting with topographical features
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemical gradients influencing catalytic Janus colloids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Complex interactions in catalytic Janus colloids
Number of subjects: 0
Study: 26739683

Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verapamil (80 mg three times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampicin (600 mg once daily)
Number of subjects: 0
Study: 25274713

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention (computer-based, 2 days a week for 60 min over 10 weeks)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention
Number of subjects: 45
Study: 22273843

Group type: EXPERIMENTAL
Intervention: NOURISH intervention targeting parents of overweight children
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (parents not participating in NOURISH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NOURISH intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 20351157

Group type: EXPERIMENTAL
Intervention: Automated paging system for critical values
Number of subjects: 108

Group type: COMPARATOR
Intervention: Usual care (telephone call to the patient's ward)
Number of subjects: 108
Study: 17394642

Group type: EXPERIMENTAL
Intervention: TSP 0.5%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TSP 1%
Number of subjects: 30

Group type: COMPARATOR
Intervention: HA 0.2%
Number of subjects: 30
Study: 15672850

Group type: EXPERIMENTAL
Intervention: Blood culture
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Sputum culture
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Serology (acute and convalescent serum samples)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Overall etiological diagnosis
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Pathogen identification
Number of subjects: 507
Study: 11713061

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 607

Group type: COMPARATOR
Intervention: Surgery (trabeculectomy with or without 5-fluorouracil)
Number of subjects: 607

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 607
Study: 9165323

Group type: EXPERIMENTAL
Intervention: 200 ml of full fat milk
Number of subjects: 48

Group type: COMPARATOR
Intervention: 200 ml of still mineral water
Number of subjects: 48
Study: 7956714

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (300 mg/day)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (AS-negative group)
Number of subjects: 27
Study: 3658570

Group type: EXPERIMENTAL
Intervention: Taurine (30 mg/kg/d)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Taurine
Number of subjects: 8
Study: 31725085

Group type: EXPERIMENTAL
Intervention: Direct lateral (DL) starting point
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Posterolateral (PL) starting point
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SNVB width
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DL 30-degree group
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: PL 0-degree group
Number of subjects: 48
Study: 31112429

Group type: EXPERIMENTAL
Intervention: Co-occurring OUD and CUD
Number of subjects: 234181

Group type: COMPARATOR
Intervention: OUD only
Number of subjects: 234181
Study: 27993298

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 273

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 273
Study: 25287712

Group type: EXPERIMENTAL
Intervention: SGA individuals
Number of subjects: 39

Group type: COMPARATOR
Intervention: AGA individuals
Number of subjects: 39
Study: 23601143

Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics therapy (IVAT) for exacerbation, duration: 14 days.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (stable patients), N=10.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physical activity monitored during IVAT using a SenseWear armband.
Number of subjects: 20
Study: 21397957

Group type: EXPERIMENTAL
Intervention: Adenoidectomy and tympanostomy tubes
Number of subjects: 87

Group type: COMPARATOR
Intervention: Adenoidectomy alone
Number of subjects: 87
Study: 19325192

Group type: EXPERIMENTAL
Intervention: Nicorandil treatment
Number of subjects: 1337
Study: 16340944

Group type: EXPERIMENTAL
Intervention: High-protein diet (1.9 g/kg BW)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal-protein diet (1.3 g/kg BW)
Number of subjects: 15
Study: 15037537

Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg/d)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Chlorthalidone (50 mg/d)
Number of subjects: 70
Study: 11130772

Group type: EXPERIMENTAL
Intervention: cilazapril (C), 2.5 mg once daily
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: cilazapril (C)
Number of subjects: 54

Group type: COMPARATOR
Intervention: placebo (P)
Number of subjects: 54
Study: 9045468

Group type: EXPERIMENTAL
Intervention: 5-FU/INF-alpha
Number of subjects: 23

Group type: COMPARATOR
Intervention: 5-FU +/- leucovorin
Number of subjects: 23
Study: 8286176

Group type: EXPERIMENTAL
Intervention: Laparoscopic Cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open Cholecystectomy
Number of subjects: 0
Study: 31166550

Group type: EXPERIMENTAL
Intervention: Intermaxillary fixation (IMF) for six weeks after mandibular setback surgery
Number of subjects: 36
Study: 29330312

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus aspirin
Number of subjects: 807

Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 807

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (clopidogrel plus aspirin)
Number of subjects: 807

Group type: COMPARATOR
Intervention: Single antiplatelet therapy (aspirin)
Number of subjects: 807
Study: 26916697

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg once daily
Number of subjects: 16

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 16
Study: 24743864

Group type: EXPERIMENTAL
Intervention: Patients with schizophrenia (n = 258)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Patients with persecutory delusions (n = 142)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Personalizing subgroup (n = 70)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Self-blaming subgroup (n = 188)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Healthy controls (n = 51)
Number of subjects: 258
Study: 22472744

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study: 20051897

Group type: EXPERIMENTAL
Intervention: Memory group intervention focusing on internal strategy use
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study: 18773723

Group type: EXPERIMENTAL
Intervention: Chromatic information (red/green) in motion integration; measured through psychophysical reports.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Luminance information (bright/dark) in motion integration; measured through psychophysical reports.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chromatic information (red/green) in motion integration; measured through eye-movement measures.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Luminance information (bright/dark) in motion integration; measured through eye-movement measures.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Luminance information (bright/dark) in motion integration; measured through eye-movement measures in 3-month-old infants.
Number of subjects: 0
Study: 16195905

Group type: EXPERIMENTAL
Intervention: Oral nystatin (3x10(6) U per day)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No nystatin (control group)
Number of subjects: 98
Study: 12860576

Group type: EXPERIMENTAL
Intervention: Eplerenone (50 mg/d, titrated to max 200 mg)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/d, titrated to max 10 mg)
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Eplerenone and Amlodipine
Number of subjects: 269
Study: 10583711

Group type: EXPERIMENTAL
Intervention: Deoxycholic acid (DCA) 750 mg day‐1 for 3 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Untreated gallstone patients
Number of subjects: 13